Guidelines of the Brazilian Dermatology Society for diagnosis, treatment and follow up of primary cutaneous melanoma - part I by Castro, Luiz Guilherme Martins et al.
  851
An Bras Dermatol. 2015;90(6):851-61.
speCiAl ArtiCle
Guidelines of the Brazilian Dermatology Society for 
diagnosis, treatment and follow up of primary 
cutaneous melanoma - Part I*
Luiz	Guilherme	Martins	Castro1,2,3	 Maria Cristina Messina1,2,3,4
Walter Loureiro5 Ricardo Silvestre Macarenco1,6
João Pedreira Duprat Neto7 Thais Helena Bello Di Giacomo1,2,3
Flávia	Vasques	Bittencourt8 Renato	Marchiori	Bakos9
Sérgio	Schrader	Serpa10 Hamilton Ometto Stolf11
Gabriel	Gontijo8
DOI: http://dx.doi.org/10.1590/abd1806-4841.20154707
Abstract:	 The	 last	Brazilian	guidelines	 on	melanoma	were	published	 in	 2002.	Development	 in	diagnosis	 and	
treatment	made	updating	necessary.	The	coordinators	elaborated	ten	clinical	questions,	based	on	PICO	system.	
A	Medline	search,	according	to	specific	MeSH	terms	for	each	of	the	10	questions	was	performed	and	articles	se-
lected	were	classified	from	A	to	D	according	to	level	of	scientific	evidence.	Based	on	the	results,	recommendations	
were	defined	and	classified	according	to	scientific	strength.	The	present	Guidelines	were	divided	in	two	parts	
for	editorial	and	publication	reasons.	In	the	first	part,	the	following	clinical	questions	were	answered:	1)	The	use	
of	dermoscopy	for	diagnosis	of	primary	cutaneous	melanoma	brings	benefits	for	patients	when	compared	with	
clinical	examination?	2)	Does	dermoscopy	favor	diagnosis	of	nail	apparatus	melanoma?	3)	Is	there	a	prognostic	
difference	when	incisional	or	excisional	biopsies	are	used?	4)	Does	revision	by	a	pathologist	trained	in	melanoma	
contribute to diagnosis and treatment of primary cutaneous melanoma? What margins should be used to treat 
lentigo maligna melanoma and melanoma in situ?
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INTRODUCTION
Cutaneous	melanoma	(CM)	is	one	of	 the	most	
potentially	dangerous	forms	of	skin	cancers,	account-
ing	 for	 approximately	 90%	of	deaths.	The	dermatol-
ogist is in the forefront of diagnosis and treatment of 
CM.	It	is	his	duty	to	keep	updated	on	best	practices	in	
diagnosis,	treatment	and	disease	monitoring	to	be	able	
to	diagnose,	treat	and	council	patients	in	the	best	way.	
The	last	Brazilian	guidelines	on	CM	were	published	in	
2002.1 Over 10 years have passed and important ad-
vances	 in	 the	area	occurred	during	 this	period,	with	
greater	 relevance	 to	diagnostic	 techniques.	Although	
some	concepts	have	not	changed,	it	is	necessary	to	up-
date the standards of practice on this important health 
problem.
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These guidelines are intended for diagnostic 
and therapeutic approach and follow-up of patients 
with	 suspected	 or	 confirmed	 diagnoses	 of	 primary	
CM	(PCM)	with	no	clinical	nor	histological	evidence	
of	metastatic	disease	(stages	0,	I	and	II).	They	do	not	
include ocular nor mucosal melanoma.
OBJECTIVE
To introduce the most advanced evidences in 
diagnosis,	 therapeutic	 management	 and	 monitoring	
of	PCM	clinical	stages	0,	I	and	II	patients,	describing	
diagnostic	 peculiarities	 that	 allow	 identification	 of	
these	tumors	in	early	stages,	as	well	as	measures	most	
widely accepted for treatment and follow-up in the 
context	of	Brazilian	dermatology.
METHOD - DESCRIPTION OF EVIDENCE COLLECTION
The	coordinators	have	defined	10	questions	that	
reflect	 issues	of	clinical	relevance	on	the	subject.	The	
questions	were	 structured	 according	 to	 the	 acronym	
PICO	(patient	or	population,	intervention,	comparison	
or	 control	and	outcome),	according	 to	 regulations	of	
the	National	Health	Agency,	the	Brazilian	Medical	As-
sociation	and	Federal	Council	of	Medicine,	described	
in	“The	process	of	development,	validation	and	imple-
mentation of clinical guidelines in the private health-
care	system	in	Brazil”.2	To	answer	 these	questions,	a	
literature	review	of	scientific	articles	was	conducted	in	
MEDLINE database. Search for evidence was limited 
primarily to articles published between 01/01/2009 
and	06/30/2014	and	keywords	(MeSH	terms)	present	
in	the	title	and/or	summary	were	used,	grouped	into	
specific	syntaxes	for	each	of	the	10	questions	alone,	as	
described in Chart 1.
After	 reading	 the	 abstracts,	 articles	 contain-
ing	information	relevant	to	the	subject	were	selected.	
When	appropriate,	references	present	in	these	papers	
were	 selected,	 without	 limit	 for	 publication	 period,	
and	were	 analyzed	 using	 the	 same	methodology	 as	
that for the primarily selected studies.
Articles	 that	 presented	 the	 expected	 contribu-
tion	were	analyzed	regarding	the	level	of	evidence	(Ta-
ble	2).	Recommendations	were	written	in	response	to	
the	questions	elaborated.	Recommendations	were	also	
graduated	according	to	level	of	evidence	(Chart	2).
RESULTS AND DISCUSSION  
Discussion	and	recommendations	for	the	first	5	
questions	appear	below.	The	other	5	questions	will	be	
presented in a new publication.
1) Is the use of dermoscopy for diagnosis of 
PCM  beneficial for patients with suspicious lesions 
when compared to clinical examination?
For many years dermatologists could only rely 
on clinical diagnosis when facing a suspicious mela-
noma	 lesion.	 Implications	of	 such	diagnosis	 justified	
extreme measures such as removal of large amounts 
of	suspicious	lesions,	which	subsequently	revealed	to	
be	benign	(unnecessary	resections).
A	major	step	in	improving	accuracy	of	diagno-
sis	of	primary	cutaneous	melanoma	(PCM)	occurred	
with	the	introduction	of	“Melanoma	ABCD”	rule,	ac-
ronym	 introduced	 in	 1985,	 using	 the	 initials	 of	 four	
clinical	features	of	skin	lesions	that	may	be	indicative	
of malignancy (Asymmetry,	irregular	Borders,	varied	
Colors and Diameter	 >6	 mm).3 Although	 increasing	
Chart 1: Terms	of	the	descriptors	used	to	research	each	question	and	number	of	selected	articles
Question Terms Number of articles
1	 (dermoscopy	OR	dermatoscopy)	AND	melanoma	AND	diagnosis	 339
2	 (dermoscopy	OR	dermatoscopy)	AND	melanoma	AND	(nail	OR	subungual)	 21
3	 (excisional	OR	incisional)	AND	melanoma	AND	biopsy	AND	prognosis	 13
4	 pathology	review	AND	melanoma	 9
5	 (therapy	OR	treatment)	AND	(lentigo	maligna	OR	melanoma	in	situ)	 903
Chart 2: Grade of recommendation and level 
of evidence:
A:		Experimental	or	observational	studies	of	higher	 
consistency.
B:  Experimental or observational studies of lower  
consistency.
C: Case reports / uncontrolled studies.
D:		Opinion	without	critical	evaluation,	based	on	consen-
sus,	physiological	studies	or	animal	models.
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diagnosis	sensitivity	and	specificity,	the	number	of	ne-
vus excised for diagnosing a melanoma was still high. 
A	 few	years	 later	 the	 letter	 “E”	was	 included	 in	 the	
acronym to represent “Evolution” or changes in the 
appearance of a suspicious lesion.4,5
Dermoscopy	(DMCP)	enables	 the	examination	
of	skin	lesions,	melanocytic	or	not,	and	the	observation	
of	structures	and	colors	of	the	epidermis,	dermo-epi-
dermal	junction	and	superficial	dermis,	not	visible	to	
the	naked	eye.	These	findings	correlate	with	histolog-
ical features and are used to determine whether the 
lesion is malignant or benign and if surgical removal is 
indicated. When integrated with information obtained 
from	the	clinical	history	and	macroscopic	examination,	
DMCP allows obtaining such a large amount of infor-
mation,	that	it	has	gradually	became	an	irreplaceable	
instrument	for	 the	dermatologist,	such	as	 the	stetho-
scope is for the clinician.
Naked	eye	diagnostic	sensitivity	for	PCM	(per-
centage	of	correctly	diagnosed	melanomas)	is	around	
71%	whereas	with	the	use	of	dermatoscope	is	90%.	A	
meta-analysis of 22 studies showed that diagnostic ac-
curacy	was	higher	than	naked	eye	examination	when	
experts	 used	 DMCP	 (sensitivity	 89%	 and	 specificity	
79%)	(level	of	evidence	A).6 There was no decrease in 
specificity,	suggesting	that	the	DMCP	increases	diag-
nostic accuracy without increasing the number of un-
diagnosed	melanomas	(level	of	evidence	A).7,8
To	 achieve	 these	 higher	 efficiency	 levels	 it	 is	
necessary	 to	 use	 an	 algorithm	 for	 analyzing	 suspi-
cious	 skin	 lesions.	 The	 4	 best	 known	 are:	 Menzies’	
scoring	method;	pattern	analysis;	7-points	check	 list;	
and	ABCD	of	DMCP,	which	 –	 it’s	 important	 to	note	
–	is	different	from	the	clinical	ABCD.9 At	a	consensus	
DMCP	experts	meeting,	 standard	analysis	algorithm	
reached	the	highest	specificity,	sensitivity	and	accura-
cy for melanoma detection when compared with the 
other	3	algorithms	(level	of	evidence	B).10	Any	of	these	
algorithms presents higher effectiveness than exam-
ination	with	naked	eye	(level	of	evidence	A).7,11-13   In 
summary,	when	using	DMCP	to	evaluate	any	suspi-
cious	lesion,	compared	with	evaluation	by	the	naked	
eye,	the	probability	of	classifying	an	actual	malignant	
lesion	as	malignant	is	higher,	as	well	as	classifying	as	
benign	a	truly	benign	lesion.	At	this	point	it	is	import-
ant to remember that even with the use of DMCP accu-
racy	of	diagnosis	melanoma	does	not	reach	100%.	This	
is	due	to	the	lack	of	dermoscopic	features	suggestive	
of the diagnosis in very early lesions or in some cases 
of	uncharacteristic	melanomas	(featureless).6,14
In addition to increased PCM diagnostic accura-
cy,	use	of	DMCP	presents	2	more	clear	benefits:	reduc-
tion of unnecessary resections and increased diagnosis 
of	non-melanoma	skin	cancer	(level	of	evidence	A).15-18	A	
randomized	study	showed	42%	decrease	in	the	number	
of unnecessary biopsies.16	This	finding	is	similar	to	a	ret-
rospective study of excisions of pigmented lesions per-
formed before and after training in DMCP. The rate of 
benign/ malignant lesions decreased from 18.0: 1 to 4.3: 
1	(level	of	evidence	A).16
Importantly,	 the	 effectiveness	 DMCP	 use	 de-
pends on formal training and experience. It was 
demonstrated that dermatologists with formal train-
ing and at least 3-years experience in DMCP reach 
higher CM detection rates than non-trained dermatol-
ogists	(level	of	evidence	B).19 This learning process is 
time consuming and in the early stages of the learning 
curve worsening of accuracy can occur.20 Dermatolo-
gists,	 physicians	 from	 other	 specialties,	 paramedical	
staff and even medical students have consistently 
improved diagnosis accuracy after being trained in 
DMCP	use	(level	of	evidence	A).	A	considerable	num-
ber	 of	 dermatologists	 believe	 that	 the	 time	 required	
for training in DMCP is excessive.21	At	the	same	time,	
some studies show a low level of satisfaction among 
chief-residents of dermatology in relation to training 
in DMCP. Many want more intense instruction in the 
area. There are also complaints about the limited avail-
ability	of	courses	(level	of	evidence	C).22
Recommendations:
•	DMCP increases diagnostic accuracy of PCM 
compared to clinical examination. It should be used 
routinely in the evaluation of melanocytic lesions 
(grade	of	recommendation	A);
•	The	 use	 of	 DMCP	 for	 this	 purpose	 requires	
specific	training	in	order	to	achieve	the	desired	accu-
racy	(grade	of	recommendation	A).
•	In addition to being useful in diagnosing 
PCM,	regular	use	of	DMCP	also	has	the	advantage	of	
reducing the number of unnecessary excisions (grade 
of	recommendation	A);
•	In addition to being useful in diagnosing PCM 
and	 reducing	 the	 number	 of	 unnecessary	 excisions,	
regular use of DMCP leads to an increase in diagnosis 
of	non-melanoma	skin	cancer	(grade	of	recommenda-
tion	A).
2) Does dermoscopy favor diagnosis of prima-
ry cutaneous melanoma of the nail apparatus (NA)?
NA-PCM	 represents	 0.7%	 to	 3.5%	of	 all	mela-
nomas.23,24	Although	deemed	little	frequent	when	con-
sidering	that	the	palm	is	equivalent	to	1%	of	the	body	
surface area and the total area of the 20 nails is much 
smaller	than	the	area	of	the	palm,	it	becomes	clear	the	
incidence	of	NA-PCM	 is	proportionally	greater	 than	
in the rest of the body.25  In	Caucasians	NA-PCM	re-
sponds	from	1,4	to	2,0%	of	all	melanomas.26,27	 	In	Af-
ro-american	population	it	is	more	frequente,	reaching	
20%	of	all	melanoma.	In	American	indians	frequency	
may	be	even	higher	(31%).28-30 In no ethnic group the 
frequency	of	NA-PCM	is	as	high	as	in	japanese	pop-
ulation.	 In	 this	 population,	 acral	 melanoma	 (which	
includes	 all	NA-PCM)	 responds	 for	 50	 to	 77%	of	 all	
melanomas.31,	32. 
Early	diagnosis	of	NA-PCM	improves	prognosis.	
However,	biopsies,	essential	 for	correct	diagnosis	and	
staging,	carry	the	possibility	of	permanent	dystrophies	
of	the	NA.	The	inherent	complexity	of	surgical	proce-
dures	in	the	NA	delays	great	part	of	melanoma	diagno-
sis	in	this	location,	closing	the	opportunity	window	for	
curative	 treatment.	 Lesions	 arousing	much	 suspicion,	
such	as	large	lesions	or	lesions	causing	nail	dystrophy,	
are	usually	biopsied.	However,	these	are	usually	associ-
ated with more advanced stages and worse prognosis.
Clinically,	subungual	melanoma	(SUM)	at	initial	
stages	 is	often	characterized	as	striated	melanonychia	
(SM),	defined	as	dark	bands	growing	in	the	longitudi-
nally	on	the	nail.	Since	it	is	not	a	pathognomonic	NA-
PCM	clinical	finding,	melanoma	associated	SM	should	
be differentiated from those of non-malignant etiology. 
Early differential diagnosis of SM still remains a chal-
lenge	 for	dermatologists,	 even	 for	nails	 experts	 (level	
of	evidence	B).33	Over	the	years,	signs	and	methods	to	
assist	the	physician	in	early	diagnosis	of	NA	melanoma	
of	have	been	sought.	Among	them	are:
a)	Clinical	examination:
Hutchinson’s	 signal	 (HS),	periungual	pigmen-
tation	with	or	without	SM,	is	historically	considered	as	
the most important clinical sign to differentiate SUM 
from benign melanocytic nevi.34,35	However,	it	is	not	a	
pathognomonic sign since it is not present in amela-
notic melanoma and can be seen in benign conditions 
such as melanocyte activation and even in benign me-
lanocytic	nevi	(level	of	evidence	A).36 HS should be dif-
ferentiated	from	pseudo-HS	(visualization	of	pigmen-
tation in nail bed or matrix due to peri-ungual tissue 
transparency)	that	may	be	present	in	Bowen’s	disease	
and in benign conditions that cause subungual hyper-
pigmentation.37,38	Topical or systemic drugs can also 
cause	SM,	which	may	or	may	not	be	associated	with	
the peri-ungual pigmentation.39-42
Clinical	examination	with	naked	eye	was	used	
for decades as the sole diagnostic method. To increase 
accuracy,	ABCDEF	rule	for	SUM	was	created,	like	the	
ABCD	rule	 for	CM.43,44	Each letter refers to a charac-
teristic	associated	with	increased	risk	for	SUM,	as	it	is	
shown in Chart 3.
b) Nail plate dermoscopy:
DMCP	plays	 a	key	 role	 in	PCM	early	diagno-
sis,	 however,	 this	 role	 is	 less	 impacting	 on	 the	 eval-
uation of SM and SUM. It’s important to remember 
that DMCP helps to differentiate melanin and blood 
(although it cannot differentiate between bleeding 
caused	by	tumor).	There	is	no	evidence	of	the	superi-
ority	of	polarized	in	relation	to	non-polarized	light	in	
the examination of SM.42
c) Intraoperative dermoscopy:
The nail plate is translucent and allows der-
moscopic	visualization	of	the	pigment	present	in	the	
nail	bed,	but	visual	characteristics	are	altered,	making	
it	difficult	to	reach	a	correct	interpretation.	If	the	nail	
plate	 is	 surgically	 removed,	 it	 is	possible	 to	perform	
direct	DMCP	on	 the	nail	bed	using	a	polarized	 light	
dermatoscope.
Studies correlating nail bed DMCP with histo-
logical evaluation of SM allowed identifying patterns 
with	high	diagnostic	 accuracy	 (level	 of	 evidence	A). 
43	 It	 is	 important	 to	 note	 that,	 intraoperative	DMCP	
does	 not	 replace	 histologic	 examination,	 which	 re-
mains the gold standard for diagnosis of SUM and 
Chart 3:	Meaning	of	the	mnemonic	method	“ABCDEF”	of	melanoma	of	the	nail	apparatus	
Letter Meaning Detailing
Age	 Most	affected	age	and	ethnicities	 	From	20	to	90	years,	with	peak	of	incidence	between	the	5th	and	7th	
decades;
	 	 African-Americans,	Asians	and	American	Indians.
Band	 Band	or	stripe	 Striation	width	equal	to	or	greater	than	3mm
	 	 Blurred	or	jagged	edges,	brown/	black	pigment.
Change	 Change/	alteration	 Rapid	growth	in	the	size	of	the	band;
	 	 Absence	of	recovery	(healing)	of	nail	dystrophy	despite	treatment.
Digit	 Finger	involved	 	Order	of	incidence:	pollex	>	hallux	>	index;	single	finger	>	several	
fingers;	dominant	hand.
Extension	 Extension	 	Pigment	extension	to	proximal,	lateral	or	hyponychium	nail	fold	
(Hutchinson’s	sign).
Family Family history Family/ personnel history of melanoma or dysplastic nevus syndrome.
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provides crucial data for evaluation of surgical mar-
gins,	therapy	and	prognosis	(level	of	evidence	B).
Tangential	excision,	also	known	as	“nail	matrix	
shave biopsy” allows the removal of lesions larger 
than	3	mm	with	minimal	risk	of	scarring	the	NA,	as	
well as enabling an assessment of safety margin (level 
of	evidence	B).	25,42-44
Recognizing	and	biopsying	SUM	in	early	stages	
is	key	to	achieving	cure	rates	similar	to	those	of	in situ 
PCM. 
Recommendations:
•	ABCDEF	rule	provides	a	methodology	for	clin-
ical evaluation of SM and increases clinical diagnosis 
sensitivity	of	SUM	(grade	of	recommendation	A).
•	nail plate DMCP increases accuracy for indi-
cating	SM	biopsies	(grade	of	recommendation	A).
•	Intraoperative DMCP has high level of accu-
racy	in	the	correlation	between	visualized	and	histo-
logical	pattern	(grade	of	recommendation	A).
•	Histologic examination still remains the gold 
standard	 for	 definitive	 diagnosis	 of	 NA	 melanoma	
(grade	of	recommendation	A).
3) Is there prognostic difference when per-
forming incisional or excisional biopsy of suspected 
melanoma lesions?
Excisional	biopsy	(EB)	with	1	to	3	mm	margins	
is	 recommended	as	first	choice	 therapy	for	pigment-
ed lesion suspected of melanoma. EB enables better 
histological	evaluation,	which	 includes:	 tumor	 thick-
ness	 (Breslow	depth),	MIand	presence	or	 absence	of	
ulceration.	These	3	items	are	essential	to	define	stag-
ing,	 prognosis	 and	 treatment.	 45 There are situations 
where	EB	is	difficult	to	perform,	such	as,	but	not	only	
extensive	 pigmented	 lesions	 on	 the	 face,	 mucous	
membranes or acral lesions or extensive lesions with 
low	suspicion	of	melanoma.	In	such	cases,	 incisional	
biopsy	(IB)	would	be	less	invasive	than	EB.46
Although	 IB	 is	 technically	 simpler	 to	 perform	
and	has	lower	cost,	a	point	that	should	be	taken	into	
consideration since healthcare resources are scarce in 
many	 countries,	 it	 allows	 only	 a	 partial	 histological	
evaluation of the lesion. 46 The concern that mechanical 
manipulation	(such	as	punch	biopsy	or	needle	biopsy)	
could	implant	neoplastic	cells	and	increase	the	risk	of	
metastases was great for many years and IB was con-
traindicated	at	that	time.	This	potential	risk	has	been	
discussed	not	only	for	melanoma,	but	also	for	various	
types of tumors.47	Presently	it	is	believed	this	risk	has	
been overestimated and there are considerations that 
tumor	 cells	 molecular	 characteristics,	 such	 as	 adhe-
sion	molecules,	matrix	metalloproteinase	and	vascu-
lar	growth	factors,	may	influence	the	ability	to	migrate	
and	to	induce	vascularization,	which	would	be	more	
important	in	disseminating	tumor	cells	than	just	me-
chanical manipulation.48
To assess whether IB resulted in worse progno-
sis	compared	to	EB,	several	retrospective	and	prospec-
tive studies were conducted.49-57	Most	of	 them,	espe-
cially	those	with	larger	numbers	of	patients,	showed	
that the type of biopsy does not play a role in the evo-
lution	of	melanoma	patients	(level	of	evidence	A).
IB	 can	 be	performed	by	 shave,	 punch	 or	 inci-
sional	 techniques.	 A	 study	 comparing	 histological	
evaluation	of	EB,	shave	biopsy,	punch	biopsy	and	IB,	
showed that treatment recommendations changed in 
6%	of	the	cases:	 (2%	after	EB,	5%	after	shave	biopsy,	
18%	after	punch	biopsy	and	18%	after	IB).	Thus,	it	was	
found that EB allows better histological evaluation 
and should be preferred whenever possible (level of 
evidence	A).58  
A	 prospective	 study	 designed	 to	 evaluate	 the	
impact	on	 staging,	area	of	margins	expansion,	 senti-
nel	 node	 positivity,	 tumor	 recurrence	 and	 survival	
evaluated 709 patients who underwent punch biopsy 
(23%),	 shave	biopsy	 (34%)	 and	EB	 (43%).	There	was	
no	significant	difference	in	accuracy	of	sentinel	lymph	
node	results,	tumor	recurrence	nor	in	patient	survival.	
The study concluded that biopsy type did not impact 
SLNB	accuracy	or	results,	tumor	recurrence,	or	prog-
nosis.	 Punch	 and	 shave	 biopsies,	when	 used	 appro-
priately,	should	not	be	discouraged	for	the	diagnosis	
of	melanoma	(level	of	evidence	A). 59
IB may be used for lesions suspected of mela-
noma	located	in	areas	where	EB	is	difficult	to	perform,	
such	 as	 –	 but	 not	 limited	 to	 –	 large	 lesions,	 lesions	
located	 on	 the	 face,	 mucous	 membranes	 and	 acral	
regions or lesions with low probability of melanoma 
(level	of	evidence	B).46 
When	 deciding	 on	 IB,	 it	 must	 be	 performed	
in locations that allow histological evaluation of the 
greater	 depth	 of	 the	 lesion	 (clinically	 darker	 areas	
and/or	papular).	DMCP	 can	be	 a	useful	 tool	 for	 se-
lecting	the	best	place	for	biopsy,	but	there	are	still	no	
studies with large number of patients that support this 
recommendation	(level	of	evidence	D). 60 
Recommendations:
•	EB	should	be	 the	preferred	 technique	when-
ever	possible,	because	it	allows	better	tumor	histolog-
ical	evaluation,	which	directly	impacts	in	the	conduct	
and	prognosis	(grade	of	recommendation	A).
•	IB does not affect prognosis of melanoma pa-
tients and can be used when necessary (grade of rec-
ommendation	A).
•	IB	 is	suggested	 in	 the	 following	cases,	but	 is	
not	limited	to	(grade	of	recommendation	B):
•	Extensive pigmented lesions with low suspi-
cion of melanoma; 
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•	Suspected extensive lentigo maligna on the 
face;
•	Suspicious	pigmented	lesions,	extensive	or	in	
an acral region; 
•	Mucosal lesions.
•	The	major	 axis	 of	 the	 biopsy	 should	 be	 ori-
ented so as to facilitate possible margins expansion. 
In	general,	when	performed	in	the	members	it	means	
along	the	major	axis	(grade	of	recommendation	C).
4)	Does	 the	 review	of	 histological	 findings	 by	
a pathologist trained in melanoma contribute to the 
diagnosis and treatment of  PCM? 
The gold-standard for PCM  diagnosis is histo-
pathology.	Roughly,	 there	 exist	 about	 20	histological	
items	to	be	evaluated	in	each	case	before	a	final	diag-
nosis	is	rendered.	This	is	a	challenging	task,	which	can	
be	 influenced	 by	 interpretation	 biases61. Experience 
and interest of general pathologists on this issue are 
heterogeneous,	as	is	the	frequency		such	a	neoplasm	is	
found in diagnostic routine in general pathology lab-
oratories.
In	 addition	 to	 correct	 diagnosis,	 it	 is	 essential	
that histologic reports on melanoma address micro-
staging	(MST)	items,	which	will	be	essential	for	deter-
mining treatment and prognosis62.  Since appropriate 
local treatment and the decision of performing senti-
nel	lymphnode	biopsy	rely	on	MST	items,		histologic	
report must include at least the following data8,	62-68: 
1. Margin involvement and margin distances 
from the neoplasm;
2. Presence or not of dermal invasion;
3. In invasive neoplasms:
a.	 Tumor	thickness	(Breslow	depth);
b.	 Mitotic	index	(MI);
c. Ulceration: present or not;
d. Microsatellitosis /satellitosis.
Studies	have	shown	that	information	on	MI,	ul-
ceration,	microsatellitosis	and	tumor	thickness	are	not	
originally included in melanoma histologic reports in 
47-50%,	13-72%,	50%,	and	29%	of	cases,	respectively.69-71 
In	order	to	reduce	such	frequencies,	some	of	the	most	
influential	 pathology	 societies	 worldwide	 created	 a	
consensus protocol on mandatory and wishful items to 
be included in melanoma histologic reports.66
Correct histological criteria to determine der-
mal	invasion,	ulceration,	and	microsatellitosis,	as	well	
as	proper	methodology	for	measuring	Breslow	thick-
ness	and	mitotic	counting	are	of	equal	importance.66-66 
Physicians reading melanoma histologic reports 
cannot	directly	check	if	proper	methodology	for	each	
item was used correctly in a given case. The only prac-
tical	way	 to	 achieve	 this	 goal	 is	 to	 request	 a	 second	
opinion to a pathologist with expertise in melanoma 
or to send the slides to a melanoma  referral hospital 
for histopathological  review. 
Indeed,	 a	 recent	 study	has	 shown	 that	 review	
of thin and in situ melanomas by an expert patholo-
gist has led to changes in diagnosis and microstaging 
with	subsequent	modification	of	original	proposed	lo-
cal	treatment	and	SLNB	in	12%	and	16%,	respectively.	
(Level	of	evidence	B).69	Similarly,	a	retrospective	large	
series	showed	that	margin	status	was	modified	in		11%	
of cases after expert review.72  
It has been shown that reporting of Breslow 
thickness,	MI,	and	ulceration	has	good	inter-observer	
reproducibility among pathologists.73-76 On the other 
hand,	microsatellitosis	remains	a	microstaging	item	of	
low reproducibility.75 This data seems very important 
because the detection of microsatellitosis in primary 
melanoma	 resection	 (or	 biopsy)	 specimen	 modifies	
pathologic	staging	from	pN0	(or	pNx)	to	pN2c.8,68,69
With regard to differential diagnoses of mela-
nocytic	 nevus	 versus	melanoma,	 studies	 report	 that	
reproducibility	 ranges	 from	 73%	 to	 97.3%	 between	
general and expert pathologists.72,75-78 It has  also been 
known	for	a	long	time	that	ambiguous	melanocytic	le-
sions can lead to diagnostic disagreement even among 
experts.79 Examples of ambiguous lesions include 
atypical nevus with severe cytological and architec-
tural	 atypia,	 atypical	 Spitz	 tumors,	 etc.	Advances	 in	
genetics	knowledge	have	brought	profound	changes	
in	the	understanding	of	these	ambiguous	lesions.	As	
a	result,	the	polarization	“melanocytic	nevus	(benign)	
versus	melanoma	(malignant)”		has	progressively	giv-
en way to the recognition of a range of intermediate 
lesions	categorized	as	low-grade	malignant	or	of	un-
certain	biological	behavior.	Although	such	lesions	do	
not	constitute	a	clinicopathological	entity,	they	form	a	
spectrum with intermediate morphological and genet-
ic aberrations lying between classical nevi and mela-
nomas.			As	a	group,	these	lesions	have	the	potential	to	
evolve with microscopic regional lymphnode metasta-
ses,	but	they	rarely	lead	patients	to	death	80.	Examples	
of	such	lesions	include	atypical	Spitz		tumors,	atypical	
blue	nevi,	and	melanocytoma	(also	known	as	epitheli-
oid blue nevus. which presents some overlap with an-
imal-type	melanoma,	according	to	some	authors)80-82.
Great	 effort	 of	 the	 scientific	 community	 has	
been made to stratify this intermediary group of le-
sions	 	 by	fluorescent	 in	 situ	 hybridization	 (FISH)	 so	
that lesions with higher probability of aggressive be-
havior	 may	 be	 detected	 and	 managed	 accordingly,	
particularly	 atypical	 Spitz	 tumors	 (level	 of	 evidence	
B)83	 .	Immunohistochemistry,	FISH,	and	other	molec-
ular	pathology	techniques	have	been	used	in	order	to	
reduce	 subjectivity	 of	morphological	 examination	 of	
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ambiguous	cases	(level	of	evidence	B)84-87.
Recommendations:
• Definite	 diagnosis	 of	 melanoma	 is	 based	 on	
histopathology of excision or biopsy specimens 
(level	of	recommendation	A);
• Melanoma histologic report must include his-
tological items of MST (level of recommenda-
tion	A).
• Histological review by an expert pathologist/ 
melanoma referral center should be sought 
whenever	possible	before	definitive	treatment	
(level	of	recommendation	B).
• Immunohistochemistry and molecular studies 
can be used to aid in the diagnosis of selected 
cases of ambiguous melanocytic lesions (level 
of	recommendation	B).	
5) What margin should lentigo maligna mela-
noma and melanoma in situ be excised with?
The primary treatment for PCM is surgical re-
section. 88,89	Historically,	through	the	20th	century,	re-
section with circumferential margin of 3-5 mm was 
indicated	for	PCM	of	any	thickness,	followed	by	graft-
ing. Rationale was based on the occurrence of “centrif-
ugal	lymphatic	spread”,	seen	in	histological	prepara-
tions of excised melanomas.90
Current recommendation is that smaller mar-
gins	are	used,	reducing	surgery	morbidity.	This	is	based	
on prospective studies comparing more conservative 
with	more	 radical	 surgeries,	 on	 randomized	 studies	
and on international consensus conferences.91-103 These 
studies	 demonstrated	 that	 histological	 findings	 will	
determine	 the	appropriate	 surgical	margins,	 and	 the	
Breslow	thickness	is	the	most	important	data	(level	of	
evidence	A).
It is important to remember that for both in situ 
and	 invasive	 melanomas,	 histological	 examination	
with	paraffin	embedded	sections	is	the	gold	standard	
for evaluation of surgical margins and that margins 
expansion surgery should be performed preferably 
between	4	to	6	weeks	from	the	initial	biopsy	(level	of	
evidence	C). 100 
Margins recommended for PCM surgical exci-
sion	appear	below	(Table	1).
There is no consensus regarding deep margins 
resection	as	it	occurs	for	lateral	margins.	Historically,	
the recommendation is that invasive PCM is resected 
until	the	muscle	fascia.	There	is,	however,	no	evidence	
confirming	that	such	action	is	necessary	in	all	cases.	A	
group	of	 experts	 recommends	 that,	whenever	possi-
ble,	resection	is	made	to	the	fascia	or	to	the	deep	sub-
cutaneous	tissue,	depending	on	tumor	location	(level	
of	evidence	B).
Although	 surgical	 resection	 is	 the	 standard	
treatment for in situ melanoma (isM)	and	for	LM,	sci-
entific	evidences	regarding	the	surgical	margins	to	be	
used are not as clear as for invasive melanomas. This 
is	 because	 it	 is	 known	 that	 large	 isM,	LM	and	 lenti-
go	maligna	melanoma	 (LMM)	often	present	 subclin-
ical	atypical	junctional	hyperplasia	in	peripheral	and	
peri-adnexal	areas	of	the	lesion,	which	can	extend	for	
several millimeters beyond the visible margins.45,101-103
Several authors agree that 5 mm margins may 
often	 be	 insufficient.	Many	 studies	 have	 shown	 that	
up	 to	20%	of	LM	require	margins	 larger	 than	5	mm,	
while	12%	of	LMM	with	Breslow	thickness	up	to	1.0	
mm	require	margins	with	more	than	10	mm	(level	of	
evidence	 B). 104	According	 to	 Kunishige	 et	 al,	 9	 mm	
margins	would	be	sufficient	in	99%	of	cases	(level	of	
evidence	B). 105
It	 is	 also	 known	 that	 recurrent	 LM	 and	LMM	
tend	 to	 require	wider	margins	 (level	 of	 evidence	B).	
The	 lack	 of	 prospective	 studies	 suggests	 that,	 in	 the	
cases of large isM,	LM	and	LMM,	the	determination	of	
the	margins	is	defined	by	consensus	of	expert	groups	
or	by	retrospective	studies	(level	of	evidence	B).
The usefulness of the various methods of mi-
crographic control of margins is very discussed. 45,101,103 
The	most	disseminated	is	Mohs’	method,	but	several	
other methods of margins micrographic control ap-
pear	 in	 the	 literature,	 with	 different	 nomenclatures	
table 1: Surgical Margins for the treatment of primary cutaneous melanoma
Breslow	thickness	(mm)	 Surgical	margin	(cm)	 Level	of	evidence
In	situ	 	 0.5	#	 	 A
Up	to	1.00	 	 1.0	 	 A
From 1.01 to 2. 00  1.0 to 2.0 *  B
More	than	2.00	 	 2.0	 	 A
t-test
*			The	surgical	margins	can	be	modified	to	contemplate	anatomical,	functional	or	aesthetic	needs.	Experts	agree	that	margins	between	1cm	and	2	cm	are	acceptable	
in	areas	where	margins	of	2	cm	would	cause	significant	aesthetic,	functional	or	anatomical	losses.	The	patient	should	be	informed	and	agree	with	the	doctor	
about the best option.
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such	 as	 3D	 histology	 method,	 Tubingen	 pie	 chart,	
staged	surgical	excision,	etc.	Micrographic	surgery	is	
a very useful method to treat lesions in areas where 
healthy	 tissue	preservation	 is	 important,	 such	as	 the	
face,	as	well	as	to	allow	greater	surgical	margins	con-
trol.		It	also	diminishes	the	risk	of	recurrence	and	may	
reduce	the	final	size	of	surgical	wounds	(level	of	evi-
dence	C).	45,101,104,106 
At	 this	point	 it	 is	 important	 to	 remember	 that	
histological	 examination	by	 conventional	 frozen	 sec-
tions are not suitable for determining surgical margins 
of	melanocytic	lesions	(level	of	evidence	A).	The	ideal	
is	to	examine	paraffin	sections.	Advances	in	IHC	tech-
niques	towards	melanocytes	identification	will	allow	
frozes	sections	to	achieve	higher	reliability	rates.107-111
Some authors recommend the use of Wood’s 
light to assist in assessing the real extent of the tumor 
(level	of	evidence	D). 112 
Use of alternative non-surgical therapeutic 
methods for treating LM or isM,	(imiquimod	and	ra-
diation)	are	justified	in	cases	where	surgery	can	cause	
great aesthetic/ functional damage or in patients un-
able to undergo surgery. 45,104 Literature presents re-
ports	of	complete	response	of	up	to	88%	of	cases,	but	
it is important to consider that it is not possible to 
obtain	 a	 complete	histological	 analysis	 of	 the	 lesion,	
thus eventual invasive melanoma foci would not be 
identified.	 Histological	 examination	 after	 treatment	
showed	persistence	of	disease	in	up	to	25%	of	treated	
patients and there were cases of LM progression to in-
vasive	melanoma.	Moreover,	diversity	of	therapeutic	
regimens and short monitoring period limit the com-
parative	studies	(level	of	evidence	C). 101
Cryosurgery	with	liquid	nitrogen	has	not	been	
adequately	 studied,	 but	 it’s	 one	more	 option.	 There	
are	no	 comparative	 long-term	 studies	on	 the	 subject	
(level	of	evidence	D). 101
Recommendation
• 	For	patients	with	 isM,	surgical	margins	of	0.5	
cm	are	sufficient	(grade	of	recommendation	B).
•  Treatment margins for large isM / LM are at 
least	0.5	cm,	and	it	may	be	necessary	to	increase	
them	(grade	of	recommendation	A).
• 	The	use	of	micrographic	surgery	techniques	for	
large	isM,	LM	and	LMM	can	assist	in	more	ac-
curate	determination	of	 surgical	margins,	 but	
paraffin	 sections	 should	 be	 used	 and,	 when	
available,	IHC	techniques	(grade	of	recommen-
dation	B).
• 	Use	of	imiquimod	to	treat	LM	or	isM,	although	
off-label,	is	justified	in	cases	where	surgery	can	
cause great aesthetic/ functional impairment 
or in patients unable to undergo surgery. Be-
cause	data	for	these	situations	are	limited,	the	
surgeon	must	make	 the	decision	with	 the	pa-
tient	(grade	of	recommendation	C).
At	 the	 end	 of	 this	 first	 part	 of	 the	 Brazilian	
guidelines	 on	 melanoma,	 it	 is	 extremely	 important	
to	point	out	that	they	are	not	intended	to	stifle	med-
ical	 practice,	 but	 to	make	 it	more	 homogeneous,	 re-
ducing uncertainty/ disagreement on good practice 
standards.	Stablishing	standards,	besides	reducing	the	
differences	 in	patient	care,	can	also	make	possible	to	
provide	options	based	on	evidence,	allowing	the	phy-
sician	to	make	decisions	about	treatment	or	diagnostic	
methods,	thus	reducing	the	strain	on	patients,	doctors	
and on the healthcare system.
These	guidelines	reflect	the	best	scientific	infor-
mation	published	about	 the	subject	 to	 the	date	of	 its	
preparation.	Nevertheless,	we	must	be	 careful	when	
interpreting	 these	 data,	 since	 the	 outcome	 of	 future	
studies can lead to changes in recommendations. In 
some	 cases,	 it	may	 be	 necessary	 not	 to	 follow	 these	
guidelines,	always	keeping	in	mind	patients`	well-be-
ing	,	as	well	as	other	special	circumstances.	q
ACKNOWLEDGEMENTS
To	the	staff	of	the	Brazilian	Society	of	Dermatol-
ogy	library,	directed	by	librarian	Vanessa	Zampier	and	
Rosalynn Leite.
An Bras Dermatol. 2015;90(6):851-61.
858 Castro LGM, Messina MC, Loureiro W, Macarenco RS, Duprat Neto JP, Di Giacomo THB, et al.  
Guidelines of the Brazilian Dermatology Society for diagnosis, treatment and follow up of primary cutaneous melanoma - Part I  859
An Bras Dermatol. 2015;90(6):851-61.
REFERENCES
1. Tovo FLR, Belfort FA, Sanches Jr JA. Melanoma cutâneo - Abordagem da lesão 
primária. Acta Oncol Bras. 2003;23:454-8.
2. Agencia Nacional de Saúde Suplementar. Associação Medica Brasileira. Conselho 
Federal de Medicina O processo de elaboração, validação e implementação das 
diretrizes clinicas na saúde suplementar no Brasil. Rio de Janeiro: ANS; 2009. 
78 p.
3. Friedman RJ, Rigel DS, Kopf AW. Early detection of malignant melanoma: the 
role of physician examination and self-examination of the skin. CA Cancer J Clin. 
1985;35:130-51.
4. Robinson JK, Turrisi R. Skills training to learn discrimination of ABCDE criteria by 
those at risk of developing melanoma. Arch Dermatol. 2006;142:447-52.
5. Abbasi NR, Shaw HM, Rigel DS, Friedman RJ, McCarthy WH, Osman I,  et al. 
Early diagnosis of cutaneous melanoma: revisiting the ABCD criteria. JAMA. 
2004;292:2771-6.
6. Kittler H, Pehamberger H, Wolff K, Binder M. Diagnostic accuracy of dermoscopy. 
Lancet Oncol. 2002;3:159-65.
7. Vestergaard ME, Macaskill P, Holt PE, Menzies SW. Dermoscopy compared with 
naked eye examination for the diagnosis of primary melanoma: a meta-analysis of 
studies performed in a clinical setting. Br J Dermatol. 2008;159:669-76. 
8. Menzies SW. Evidence-based dermoscopy. Dermatol Clin. 2013;31:521-4, vii. 
9. Nachbar F, Stolz W, Merkle T, Cognetta AB, Vogt T, Landthaler M, et al. The 
ABCD rule of dermatoscopy. High prospective value in the diagnosis of doubtful 
melanocytic skin lesions. J Am Acad Dermatol. 1994;30:551-9.
10. Argenziano G, Soyer HP, Chimenti S, Talamini R, Corona R, Sera F, et al. 
Dermoscopy of pigmented skin lesions: results of a consensus meeting via the 
Internet. J Am Acad Dermatol. 2003;48:679-93.
11. Westerhoff K, McCarthy WH, Menzies SW. Increase in the sensitivity for 
melanoma diagnosis by primary care physicians using skin surface microscopy. 
Br J Dermatol. 2000;143:1016-20.
12. Argenziano G, Fabbrocini G, Carli P, De Giorgi V, Sammarco E, Delfino M. 
Epiluminescence microscopy for the diagnosis of doubtful melanocytic lesions. 
Comparison of the ABCD rule of dermatoscopy and a new 7-point checklist based 
on pattern analysis. Arch Dermatol. 1998;134:1563-70.
13. Dolianitis C, Kelly J, Wolfe R, Simpson P. Comparative performance of 4 
dermoscopic algorithms by nonexperts for the diagnosis of melanocytic lesions. 
Arch Dermatol. 2005;141:1008-14.
14. Carli P, de Giorgi V, Chiarugi A, Nardini P, Weinstock MA, Crocetti E, et al. Addition 
of dermoscopy to conventional naked-eye examination in melanoma screening: a 
randomized study. J Am Acad Dermatol. 2004;50:683-9.
15. Menzies SW, Zalaudek I. Why perform dermoscopy? The evidence for its role in the 
routine management of pigmented skin lesions. Arch Dermatol. 2006;142:1211-2.
16. Carli P, De Giorgi V, Crocetti E, Mannone F, Massi D, Chiarugi A, et al. Improvement 
of malignant/benign ratio in excised melanocytic lesions in the ‘dermoscopy era’: 
a retrospective study 1997-2001. Br J Dermatol. 2004;150:687-92.
17. van der Rhee JI, Bergman W, Kukutsch NA. The impact of dermoscopy on the 
management of pigmented lesions in everyday clinical practice of general 
dermatologists: a prospective study. Br J Dermatol. 2010;162:563-7.
18. Moulin C, Poulalhon N, Duru G, Debarbieux S, Dalle S, Thomas L. Dermoscopy 
use by French private practice dermatologists: a nationwide survey. Br J Dermatol. 
2013;168:74-9. 
19. Binder M, Schwarz M, Winkler A, Steiner A, Kaider A, Wolff K, et al. Epiluminescence 
microscopy. A useful tool for the diagnosis of pigmented skin lesions for formally 
trained dermatologists. Arch Dermatol. 1995;131:286-91.
20. Piccolo D, Ferrari A, Peris K, Diadone R, Ruggeri B, Chimenti S. Dermoscopic 
diagnosis by a trained clinician vs a clinician with minimal dermoscopy training vs 
computer-aided diagnosis of 341 pigmented skin lesions: a comparative study. Br 
J Dermatol. 2002;147:481-6.
21. Noor O 2nd, Nanda A, Rao BK. A dermoscopy survey to assess who is using it 
and why it is or is not being used. Int J Dermatol. 2009;48:951-2. 
22. Wu TP, Newlove T, Smith L, Vuong CH, Stein JA, Polsky D. The importance of 
dedicated dermoscopy training during residency: a survey of US dermatology 
chief residents. J Am Acad Dermatol. 2013;68:1000-5.
23. Finley RK 3rd, Driscoll DL, Blumenson LE, Karakousis CP. Subungual melanoma: 
an eighteen-year review. Surgery. 1994;116:96-100.
24. Quinn MJ, Thompson JE, Crotty K, McCarthy WH, Coates AS. Subungual 
melanoma of the hand. J Hand Surg Am. 1996;21:506-11.
25. Haneke E. Ungueal melanoma - controversies in diagnosis and treatment. 
Dermatol Ther. 2012;25:510-24.
26. Banfield CC, Redburn JC, Dawber RP. The incidence and prognosis of nail 
apparatus melanoma. A retrospective study of 105 patients in four English 
regions. Br J Dermatol. 1998;139:276-9.
27. O’Leary JA, Berend KR, Johnson JL, Levin LS, Seigler HF. Subungual melanoma. 
A review of 93 cases with identification of prognostic variables. Clin Orthop Relat 
Res. 2000;378:206-12.
28. Baran R, Kechijian P. Longitudinal melanonychia (melanonychia striata): diagnosis 
and management. J Am Acad Dermatol. 1989;21:1165-75.
29. Thai KE, Young R, Sinclair RD. Nail apparatus melanoma. Australas J Dermatol. 
2001;42:71-81
30. Black WC, Wiggins C. Melanoma among southwestern American Indians. Cancer. 
1985;55:2899-902.
31. Seui M, Takematsu H, Hosokawa M, Obata M, Tomita Y, Kato T, et al. Acral 
melanoma in Japan. J Invest Dermatol. 1983;80:56s-60s.
32. Ishihara K, Saida T, Otsuka F, Yamazaki N; Prognosis and Statistical Investigation 
Committee of the Japanese Skin Cancer Society. Statistical profiles of malignant 
melanoma and other skin cancers in Japan: 2007 update. Int J Clin Oncol. 
2008;13:33-41.
33. Di Chiacchio N, Hirata SH, Enokihara MY, Michalany NS, Fabbrocini G, Tosti A. 
Dermatologists’ accuracy in early diagnosis of melanoma of the nail matrix. Arch 
Dermatol. 2010;146:382-7. 
34. Fitzpatrick TB, Eisen AZ, Wolff K, Freedberg IM, Austen KF. Dermatology in general 
medicine. 7th ed. McGraw-Hill: New York; 2008.
35. Saida T, Ohshima Y. Clinical and histopathologic characteristics of early lesions of 
subungual malignant melanoma. Cancer. 1989;63:556-60.
36. Kawabata Y, Ohara K, Hino H, Tamaki K. Two kinds of Hutchinson’s sign, benign 
and malignant. J Am Acad Dermatol. 2001;44:305-7.
37. Baran R Kechijian P. Hutchinson’s sign: a reappraisal. J Am Acad Dermatol. 
1996;34:87-90.
38. Braun RP, Baran R, Le Gal FA, Dalle S, Ronger S, Pandolfi R, et al. Diagnosis and 
management of nail pigmentations. J Am Acad Dermatol. 2007;56:835-47.
39. Mooney E, Bennett RG. Periungual hyperpigmentation mimicking Hutchinson’s 
sign associated with minocycline administration. J Dermatol Surg Oncol. 
1988;14:1011-3.
40. Levit EK, Kagen MH, Scher RK, Grossman M, Altman E. The ABC rule for clinical 
detection of subungual melanoma. J Am Acad Dermatol. 2000;42:269-74.
41. Tan KB, Moncrieff M, Thompson JF, McCarthy SW, Shaw HM, Quinn MJ, et al. 
Subungual melanoma: a study of 124 cases highlighting features of early lesions, 
potential pitfalls in diagnosis, and guidelines for histologic reporting. Am J Surg 
Pathol. 2007;31:1902-12.
42. Di Chiacchio ND, Farias DC, Piraccini BM, Hirata SH, Richert B, Zaiac M, et 
al. Consensus on melanonychia nail plate dermoscopy. An Bras Dermatol. 
2013;88:309-13.
43. Hirata SH, Yamada S, Enokihara MY, Di Chiacchio N, de Almeida FA, Enokihara 
MM, et al. Patterns of nail matrix and bed of longitudinal melanonychia by 
intraoperative dermatoscopy. J Am Acad Dermatol. 2011;65:297-303.
44. Di Chiacchio N, Loureiro WR, Michalany NS, Kezam Gabriel FV. Tangential Biopsy 
Thickness versus Lesion Depth in Longitudinal Melanonychia: A Pilot Study. 
Dermatol Res Pract. 2012;2012:353864
45. Coit DG, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE 3rd, Daud A, et al. 
Melanoma,version2.2013: featured updates to the NCCN guidelines. J Natl Compr 
Canc Netw. 2013;11:395-407.
46. Pflugfelder A, Weide B, Eigentler TK, Forschner A, Leiter U, Held L, et al. Incisional 
biopsy and melanoma prognosis: facts and controversies. Clin Dermatol. 
2010;28:316-8. 
47. Fentiman IS, Millis RR, Chaudary MA, King RJ, Miller KJ, Hayward JL. Effect of the 
method of biopsy on prognosis and reliability of receptor assays in patients with 
operable breast cancer. Br J Surg. 1986;73:610-2.
48. Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature. 
2001;411:342-8.
49. Molenkamp BG, Sluijter BJ, Oosterhof B, Meijer S, van Leeuwen PA. Non-radical 
diagnostic biopsies do not negatively influence melanoma patient survival. Ann 
Surg Oncol. 2007;14:1424-30.
50. Martin RC 2nd, Scoggins CR, Ross MI, Reintgen DS, Noyes RD, Edwards MJ, 
et al. Is incisional biopsy of melanoma harmful? Am J Surg. 2005;190:913-7.
51. Bong JL, Herd RM, Hunter JA. Incisional biopsy and melanoma prognosis. J Am 
Acad Dermatol. 2002;46:690-4.
52. Austin JR, Byers RM, Brown WD, Wolf P. Influence of biopsy on the prognosis of 
cutaneous melanoma of the head and neck. Head Neck. 1996;18:107-17.
53. Lees VC, Briggs JC. Effect of initial biopsy procedure on prognosis in stage I 
invasive cutaneous malignant melanoma: review of 1086 patients. Br J Surg. 
1991;78:1108-10.
54. Lederman JS, Sober AJ. Does biopsy type influence survival in clinical stage I 
cutaneous melanoma? J Am Acad Dermatol. 1985;13:983-7.
55. Griffiths RW, Briggs JC. Biopsy procedures, primar y wide excisional surgery 
and long term prognosis in primary clinical stage I invasive cutaneous malignant 
melanoma. Ann R Coll Surg Engl. 1985;67:75-8.
56. Rampen FH, van Houten WA, Jop WC. Incisional procedures and prognosis in 
malignant melanoma. Clin Exp Dermatol. 1980;5:313-20.
57. Epstein E, Bragg K, Linden G. Biopsy and prognosis of malignant melanoma. 
JAMA. 1969;208:1369-71.
58. Hieken TJ, Hernández-Irizarry R, Boll JM, Jones Coleman JE. Accuracy of 
diagnostic biopsy for cutaneous melanoma: implications for surgical oncologists. 
Int J Surg Oncol. 2013;2013:196493.
59. Mills JK, White I, Diggs B, Fortino J, Vetto JT. Effect of biopsy type on outcome 
in the treatment of primary cutaneous melanoma. Am J Surg. 2013;205:585-90.
60. Bomm L, Benez MD, Maceira JM, Succi IC, Scotelaro Mde F. Biopsy guided by 
dermoscopy in cutaneous pigmented lesion - case report. An Bras Dermatol. 
2013;88:125-7.
61. Scolyer RA, Prieto VG. Melanoma pathology: important issues for clinicians 
involved in the multidisciplinary care of melanoma patients. Surg Oncol Clin N 
Am. 2011;20:19-37.
62. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, et al. 
Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 
2009;27:6199-206.
63. Cap.org [Internet]. Protocol for the examination of specimens from patients with 
melanoma of the skin. College of American Pathologists, 2013. [cited 2014 Jun 
30]. Available from: http://www.cap.org/apps/docs/committees/cancer/ cancer_
protocols/2013/SkinMelanoma_13protocol_3300.pdf. 
64. Rcpa.edu.au [Internet]. Primary cutaneous melanoma structured reporting 
protocol. 2nd ed. Royal College of Pathologists of Australasia, 2013. [cited 2014 
Jun 30].  Available from: http://www.rcpa.edu.au/getattachment/5961bf31-198d-
4eb0-a0f3-1cdf868a26ac/Protocol-primary-cutaneous-melanoma.aspx. 
65. Rcpath.org [Internet]. Dataset for the histopathological reporting of primary 
cutaneous malignant melanoma and regional lymph nodes. 3rd ed. Royal College 
of Pathologists, 2014. [cited 2014 Jun 30]. Available from: http://www.rcpath.org/
publications-media/publications/datasets. 
66. Scolyer RA, Judge MJ, Evans A, Frishberg DP, Prieto VG, Thompson JF, et al. 
International Collaboration on Cancer Reporting. Dataset for pathology reporting 
of cutaneous invasive melanoma: recommendations from the international 
collaboration on cancer reporting (ICCR). Am J Surg Pathol. 2013;37:1797-814.
67. Bacchi CE, Melo CRA, de Franco MF, Artigiani Neto R. Manual de Padronização de 
Laudos Histopatológicos. Sociedade Brasileira de Patologia. 4. ed. Barueri (SP): 
Manole; 2014. Capítulo 1,  Melanoma; p.1-12.
68. Dummer R, Hauschild A, Guggenheim M, Keilholz U, Pentheroudakis G; ESMO 
Guidelines Working Group. Cutaneous melanoma: ESMO Clinical Practice 
Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23:vii86-91.
69. Santillan AA, Messina JL, Marzban SS, Crespo G, Sondak VK, Zager JS. Pathology 
review of thin melanoma and melanoma in situ in a multidisciplinary melanoma 
clinic: impact on treatment decisions. J Clin Oncol. 2010;28:481-6.
70. Thompson B, Austin R, Coory M, Aitken JF, Walpole E, Francis G, et al. 
Completeness of histopathology reporting of melanoma in a high-incidence 
geographical region. Dermatology. 2009;218:7-14. 
71. Busam KJ. Lack of relevant information for tumor staging in pathology reports of 
primary cutaneous melanoma. Am J Clin Pathol. 2001;115:743-6.
72. Niebling MG, Haydu LE, Karim RZ, Thompson JF, Scolyer RA. Pathology review 
significantly affects diagnosis and treatment of melanoma patients: an analysis 
of 5011 patients treated at a melanoma treatment center. Ann Surg Oncol. 
2014;21:2245-51.
73. Scolyer RA, Shaw HM, Thompson JF, Li LX, Colman MH, Lo SK, et al. Interobserver 
reproducibility of histopathologic prognostic variables in primary cutaneous 
melanomas. Am J Surg Pathol. 2003;27:1571-6.
74. Niebling MG, Haydu LE, Karim RZ, Thompson JF, Scolyer RA. Reproducibility of 
AJCC staging parameters in primary cutaneous melanoma: an analysis of 4,924 
cases. Ann Surg Oncol. 2013;20:3969-75. 
75. Monshizadeh L, Hanikeri M, Beer TW, Heenan PJ. A critical review of melanoma 
pathology reports for patients referred to the Western Australian Melanoma 
Advisory Service. Pathology. 2012;44:441-7.
76. Shoo BA, Sagebiel RW, Kashani-Sabet M. Discordance in the histopathologic 
diagnosis of melanoma at a melanoma referral center. J Am Acad Dermatol. 
2010;62:751-6.
77. McGinnis KS, Lessin SR, Elder DE, Guerry D 4th, Schuchter L, Ming M, et al. 
Pathology review of cases presenting to a multidisciplinary pigmented lesion 
clinic. Arch Dermatol. 2002;138:617-21.
78. van Dijk MC, Aben KK, van Hees F, Klaasen A, Blokx WA, Kiemeney LA, LA et al. 
Expert review remains important in the histopathological diagnosis of cutaneous 
melanocytic lesions. Histopathology. 2008;52:139-46.
79. Farmer ER, Gonin R, Hanna MP. Discordance in the histopathologic diagnosis 
of melanoma and melanocytic nevi between expert pathologists. Hum Pathol. 
1996;27:528-31.
80. Cerroni L, Barnhill R, Elder D, Gottlieb G, Heenan P, Kutzner H, et al. Melanocytic 
tumors of uncertain malignant potential: results of a tutorial held at the XXIX 
Symposium of the International Society of Dermatopathology in Graz, October 
2008. Am J Surg Pathol. 2010;34:314-26.
81. Gerami P, Busam K, Cochran A, Cook MG, Duncan LM, Elder DE, et al. 
Histomorphologic Assessment and Interobserver Diagnostic Reproducibility of 
Atypical Spitzoid Melanocytic Neoplasms With Long-term Follow-up. Am J Surg 
Pathol. 2014;38:934-40. 
82. Mandal RV, Murali R, Lundquist KF, Ragsdale BD, Heenan P, McCarthy SW, et 
al. Pigmented epithelioid melanocytoma: favorable outcome after 5year follow-up 
Am J Surg Pathol. 2009;33:1778-82.
83. Gerami P, Scolyer RA, Xu X, Elder DE, Abraham RM, Fullen D, et al. Risk 
assessment for atypical spitzoid melanocytic neoplasms using FISH to identify 
chromosomal copy number aberrations. Am J Surg Pathol. 2013;37:676-84. 
84. Tetzlaff MT, Wang WL, Milless TL, Curry JL, Torres-Cabala CA, McLemore MS, 
et al. Ambiguous melanocytic tumors in a tertiary referral center: the contribution 
of fluorescence in situ hybridization (FISH) to conventional histopathologic and 
immunophenotypic analyses. Am J Surg Pathol. 2013;37:1783-96
85. Bastian BC, LeBoit PE, Hamm H, Bröcker EB, Pinkel D. Chromosomal gains 
and losses in primary cutaneous melanomas detected by comparative genomic 
hybridization Cancer Res. 1998;58:2170-5.
86. Gerami P, Jewell SS, Morrison LE, Blondin B, Schulz J, Ruffalo T,  et al. 
Fluorescence in situ hybridization (FISH) as an ancillary diagnostic tool in the 
diagnosis of melanoma. Am J Surg Pathol. 2009;33:1146-56.
87. North JP, Garrido MC, Kolaitis NA, LeBoit PE, McCalmont TH, Bastian BC. 
Fluorescence in situ hybridization as an ancillary tool in the diagnosis of 
ambiguous melanocytic neoplasms: a review of 804 cases. Am J Surg Pathol. 
2014;38:824-31.
88. Saiag P, Bosquet L, Guillot B, Verola O, Avril MF, Bailly C, et al. Management of 
adult patients with cutaneous melanoma without distant metastasis.2005 update 
of the French Standards, Options and Recommendations guidelines. Summary 
report. Eur J Dermatol. 2007;17:325-31. 
89. Hauschild A, Rosien F, Lischner S. Surgical standards in the primary care of 
melanoma patients. Onkologie. 2003;26:218-22.
90. Handley WS. The pathology of melanotic growths in relation to their operative 
treatment. Lancet. 1907;1:927-96.
91. Khayat D, Rixe O, Martin G, Soubrane C, Banzet M, Bazex JA, et al. French Group 
of Research on Malignant Melanoma. Surgical margins in cutaneous melanoma 
(2 cm versus 5 cm for lesions measuring less than 2.1-mm thick). Cancer. 
2003;97:1941-6.
92. Ringborg U, Andersson R, Eldh J, Glaumann B, Hafström L, Jacobsson S, et al. 
Resection margins of 2 versus 5 cm for cutaneous malignant melanoma with a 
tumor thickness of 0.8 to 2.0. mm: randomized study by the Swedish Melanoma 
Study Group. Cancer. 1996;77:1809-14.
93. Cohn-Cedermark G, Rutqvist LE, Andersson R, Breivald M, Ingvar C, Johansson 
H, et al. Long term results of a randomized study by the Swedish Melanoma 
Study Group on 2-cm versus 5-cm resection margins for patients with cutaneous 
melanoma with a tumor thickness of 0.8-2.0 mm. Cancer. 2000;89:1495-501.
94. Veronesi U, Cascinelli N, Adamus J, Balch C, Bandiera D, Barchuk A, et al. Thin 
stage I primary cutaneous malignant melanoma. Comparison of excision with 
margins of 1 or 3 cm. N Engl J Med. 1988;318:1159-62.
95. Veronesi U, Cascinelli N. Narrow excision (1-cm margin). A safe procedure for thin 
cutaneous melanoma. Arch Surg. 1991;126:438-41.
96. Cascinelli N. Margin of resection in the management of primary melanoma. Semin 
Surg Oncol. 1998;14:272-5.
97. Balch CM, Urist MM, Karakousis CP, Smith TJ, Temple WJ, Drzewiecki K, et al. 
Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 
to 4 mm). Results of a multi-institutional randomized surgical trial. Ann Surg. 
1993;218:262-7.
98. Karakousis CP, Balch CM, Urist MM, Ross MM, Smith TJ, Bartolucci AA. Local 
recurrence in malignant melanoma: long-term results of the multi institutional 
randomized surgical trial. Ann Surg Oncol. 1996;3:446-52.
99. Thomas JM, Newton-Bishop J, A’Hern R, Coombes G, Timmons M, et al. Excision 
margins in high-risk malignant melanoma. N Engl J Med. 2004;350:757-66.
100. Garbe C, Hauschild A, Volkenandt M, Schadendorf D, Stolz W, Reinhold U, et 
al. Evidence and interdisciplinary consensus-based German guidelines: surgical 
treatment and radiotherapy of melanoma. Melanoma Res. 2008;18:61-7.
101. Marsden JR, Newton-Bishop JA, Burrows L, Cook M, Corrie PG, Cox NH, et al. 
Revised U.K. guidelines for the management of cutaneous melanoma 2010. Br J 
Dermatol. 2010;163:238-56. 
102. Cancer Council Australia., Ministry of Health.; Melanoma Network (N.S.W.); 
Cancer Institute NSW., New Zealand Guidelines Group. Clinical Practice Guidelines 
for the Management of Melanoma in Australia and New Zealand: Evidence-based 
Best Practice Guidelines. Sydney, N.S.W. : Cancer Council Australia: Ministry of 
Health, 2008.
103. Négrier S, Saiag P, Guillot B, Verola O, Avril MF, Bailly C, et al. Guidelines for clinical 
practice. Standards, options and Recommendations 2005 for the management 
An Bras Dermatol. 2015;90(6):851-61.
860 Castro LGM, Messina MC, Loureiro W, Macarenco RS, Duprat Neto JP, Di Giacomo THB, et al.  
Mailing  address:
Luiz Guilherme Martins Castro
Rua Mato Grosso 306 cj 604
01239-040 - São Paulo - SP
Brazil 
Email: lgmc@oncoderma.com.br
How to cite this article: Castro	LGM,	Messina	MC,	Loureiro	W,	Macarenco	RS,	Duprat	Neto	JP,	Di	Giacomo	THB,	
Bittencourt	 FV,	 Bakos	RM,	 Serpa	 SS,	 Stolf	HO,	Gontijo	G.	Guidelines	 of	 the	Brazilian	Dermatology	 Society	 for	
diagnosis,	treatment	and	follow	up	of	primary	cutaneous	melanoma.	Part	I.	An	Bras	Dermatol.	2015;90(6):851-61.
of adult patients exhibiting an M0 cutaneous melanoma, full report. national 
Federation of Cancer Campaign Centers. French Dermatology Society. Update 
of the 1995 consensus Conference and the 1998 standards, options, and 
recommendations. Ann Dermatol Venereol. 2005;132:10S3-10S85.
104. Erickson C, Miller SJ. Treatment options in melanoma in situ: topical and radiation 
therapy, excision and Mohs surgery. Int J Dermatol. 2010;49:482-91. 
105. Kunishige JH, Brodland DG, Zitelli JA. Surgical margins for melanoma in situ. J Am 
Acad Dermatol. 2012;66:438-44. 
106. Möhrle M.J Micrographic controlled surgery (3D-histology) in cutaneous 
melanoma. J Dtsch Dermatol Ges. 2003;1:869-75.
107. Chang KH, Finn DT, Lee D, Bhawan J, Dallal GE, Rogers GS. Novel 16-minute 
technique for evaluating melanoma resection margins during Mohs surgery. J Am 
Acad Dermatol. 2011;64:107-12.
108. Kimyai-Asadi A, Ayala GB, Goldberg LH, Vujevich J, Jih MH. The 20-minute rapid 
MART-1 immunostaing for malignant melanoma frozen sections. Dermatol Surg. 
2008;34:498-500.
109. Kelley LC, Starkus L.Immunohistochemical staining of lentigo maligna during 
Mohs micrographic surgery using MART-1. J Am Acad Dermatol. 2002 
Jan;46(1):78-84.
110. Newman J, Beal M, Schram SE, Lee PK. Mohs micrographic surgery for lentigo 
maligna and lentigo maligna melanoma using Mel-5 immunostaining: an update 
from the University of Minnesota. Dermatol Surg. 2013;39:1794-9. 
111. Glass LF, Raziano RM, Clark GS, Higgins HW, Ladd S, Lien MH,  et al. Rapid 
frozen section immunostaining of melanocytes by microphthalmia-associated 
transcription factor. Am J Dermatopathol. 2010;32:319-25.
112. Paraskevas LR, Halpern AC, Marghoob AA. Utility of the Wood’s light: five cases 
from a pigmented lesion clinic. Br J Dermatol. 2005;152:1039-44.
Guidelines of the Brazilian Dermatology Society for diagnosis, treatment and follow up of primary cutaneous melanoma - Part I  861
An Bras Dermatol. 2015;90(6):851-61.
